
BIOLARGO, INC.
100
Recent news coverage includes general market and industry updates with limited direct information on BioLargo’s operational developments. Notable is the CEO’s appointment to a government advisory committee and quarterly earnings reporting.
- BioLargo CEO Dennis Calvert was appointed to the U.S. Department of Commerce’s Environmental Technology Trade Advisory Committee (ETTAC) for a two-year term starting January 2025, serving as Chairman of the Enabling Innovative Technology Subcommittee [N1].
- BioLargo reported quarterly earnings results as of March 31, 2025, with financial details disclosed in SEC filings [N1].
- Recent news headlines primarily cover broader market and industry topics without specific updates on BioLargo’s business operations [N1].
BioLargo, Inc. is a Delaware-based company engaged in advanced disinfection technology and related product development, including proprietary iodine-based solutions and CupriDyne technology. The company operates through subsidiaries such as Clyra Medical Technologies and Biolargo Energy Technologies Inc. Its leadership team combines scientific expertise, entrepreneurial experience, and financial management. The company has a history of product innovation and holds patents related to its core technologies. BioLargo is publicly traded on the OTCQX under the ticker BLGO and files regular reports with the SEC, including annual and quarterly filings that disclose financial performance and governance details.
BioLargo, Inc. is a publicly traded company on the OTCQX with detailed disclosures in its 2025 10-K/A and 2026 Q3 10-Q filings. The company reported $12.23 million in revenue for fiscal year 2023 and a net loss of $15.189 million for fiscal year 2025. As of September 30, 2026, BioLargo had $1.533 million in cash and cash equivalents, current assets of $3.545 million, and current liabilities of $5.936 million, resulting in a current ratio of 0.6 and a cash ratio of 0.26. The company’s leadership includes CEO Dennis Calvert, who has served since 2002 and holds roles across subsidiaries. The company’s core technology includes advanced iodine disinfection and CupriDyne products. Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
BioLargo’s established proprietary technology in iodine disinfection and CupriDyne products, combined with a leadership team experienced in science and business, provides a foundation for continued product development and potential market expansion. The company’s engagement with government advisory committees and industry groups may enhance its visibility and credibility in clean technology sectors. Its diversified subsidiaries and product portfolio could support multiple revenue streams.
BioLargo has reported net losses and a current ratio below 1, indicating liquidity challenges. The company’s financial position shows current liabilities exceeding current assets as of September 30, 2026. The niche nature of its technology and reliance on continued innovation and market acceptance pose execution risks. Limited public market liquidity and OTCQX listing may constrain capital access. The company’s financial disclosures indicate ongoing operating losses, which may pressure resources and require additional financing.
BioLargo’s moat is based on its proprietary iodine disinfection technology and CupriDyne products, supported by patents and ongoing research and development. The company’s leadership includes founders and inventors with deep technical knowledge and experience in the field. Its technology addresses specialized disinfection needs, potentially differentiating it from competitors. The company’s involvement in clean technology trade advisory committees and industry associations may support its market positioning and innovation pipeline.
• Liquidity Risk: As of September 30, 2026, BioLargo’s current ratio was 0.6 and cash ratio was 0.26, indicating potential short-term liquidity constraints given current liabilities exceed current assets.
• Operating Losses: The company reported a net loss of $15.189 million for fiscal year 2025 and negative earnings per share in Q3 2026, reflecting ongoing profitability challenges.
• Market and Execution Risk: BioLargo operates in specialized technology sectors requiring continued innovation and market acceptance, which may present execution risks and competitive pressures.
• Capital Access: Being listed on the OTCQX and having limited market capitalization may restrict access to capital markets and financing options.
Business trends: Continued focus on proprietary iodine disinfection and CupriDyne technology development with engagement in clean technology sectors.
Execution milestones: Maintaining regulatory compliance and advancing product innovation while managing liquidity and operational costs.
Key risks: Liquidity constraints, ongoing operating losses, market acceptance of niche technologies, and capital access limitations.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- BioLargo, Inc. is a Delaware corporation with principal executive offices in Westminster, California.
- The company is publicly traded on the OTCQX under the ticker BLGO.
- As of April 29, 2026, BioLargo had 320,883,262 shares outstanding with no preferred shares issued or outstanding.
- The company is classified as a smaller reporting company and is not a shell company.
- Dennis P. Calvert serves as President, CEO, Chairman, and Director since June 2002, with extensive entrepreneurial and industry experience.
- Kenneth R. Code is Chief Science Officer and largest stockholder, founder of IOWC, which developed the company's core iodine technology acquired in 2007.
- Joseph L. Provenzano is Executive Vice President, Corporate Secretary, and Director, involved in product development and patents related to CupriDyne technology.
- The board includes directors with expertise in finance, governance, marketing, and clean technology sectors.
- Charles K. Dargan II is CFO since 2008 with a background in finance and investment banking.
- The company’s revenue for fiscal year 2023 was $12.23 million USD.
- The net income reported for fiscal year 2025 was a loss of $15.189 million USD.
- As of September 30, 2026, the company had cash and cash equivalents of $1.533 million USD and current assets of $3.545 million USD.
- Current liabilities as of September 30, 2026, were $5.936 million USD, resulting in a current ratio of 0.6 and a cash ratio of 0.26.
- Basic earnings per share for Q3 2026 was -$0.01 USD.
- The company operates subsidiaries including Clyra Medical Technologies and Biolargo Energy Technologies Inc.
- BioLargo’s CEO Dennis Calvert was appointed to the U.S. Department of Commerce’s Environmental Technology Trade Advisory Committee (ETTAC) for a two-year term starting January 2025.
- The company has a history of product development in advanced iodine disinfection and CupriDyne technology.
- BioLargo’s board and executive team have diverse expertise in science, finance, governance, and marketing.
- The company has disclosed no material legal proceedings involving directors or executive officers in the past ten years.
- Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Generated 2026-11-17
- S1 | 2026-04-30 | 10-K/A
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-11-17 | www.nasdaq.com | Nvidia's Biggest Jensen Huang Problem Was Hiding in Plain Sight | https://www.nasdaq.com/articles/nvidias-biggest-jensen-huang-problem-was-hiding-plain-sight
- N2 | 2026-11-17 | www.nasdaq.com | NextSource Materials Inc. Q1 Loss Declines | https://www.nasdaq.com/articles/nextsource-materials-inc-q1-loss-declines
- N3 | 2026-11-17 | www.nasdaq.com | Largo Inc. Q3 Loss Decreases | https://www.nasdaq.com/articles/largo-inc-q3-loss-decreases
- N4 | 2026-11-17 | www.nasdaq.com | Australian Market Extends Early Losses In Mid-market | https://www.nasdaq.com/articles/australian-market-extends-early-losses-mid-market-6
- N5 | 2026-11-17 | www.nasdaq.com | Rocket Lab Hit 100 Launches Faster Than Any Other Commercially Developed Rocket. I'd Buy a Small Stake. | https://www.nasdaq.com/articles/rocket-lab-hit-100-launches-faster-any-other-commercially-developed-rocket-id-buy-small
- N6 | 2026-11-17 | www.nasdaq.com | Soybeans Closes Lower, Despite Record NOPA Crush | https://www.nasdaq.com/articles/soybeans-closes-lower-despite-record-nopa-crush
- N7 | 2026-11-17 | www.nasdaq.com | Air Industries Group Reminds Investors of November 18 Special Meeting for Proposed Tenax Merger | https://www.nasdaq.com/articles/air-industries-group-reminds-investors-november-18-special-meeting-proposed-tenax-merger
- N8 | 2026-11-17 | www.nasdaq.com | Unicycive Therapeutics Announces FDA Acceptance of OLC NDA Resubmission and Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/unicycive-therapeutics-announces-fda-acceptance-olc-nda-resubmission-and-third-quarter
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


